AAPG Stock - ASCENTAGE PHARMA GROUP INTERNATIONAL
Unlock GoAI Insights for AAPG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $980.65M | $221.98M | $209.71M | $27.91M | $12.45M |
| Gross Profit | $951.57M | $191.44M | $187.71M | $24.58M | $10.48M |
| Gross Margin | 97.0% | 86.2% | 89.5% | 88.1% | 84.2% |
| Operating Income | $-369,730,000 | $-872,636,000 | $-849,810,000 | $-869,835,000 | $-663,941,000 |
| Net Income | $-405,433,000 | $-925,637,000 | $-882,924,000 | $-782,424,000 | $-677,606,000 |
| Net Margin | -41.3% | -417.0% | -421.0% | -2803.4% | -5442.6% |
| EPS | $-1.34 | $-13.12 | $-13.40 | $-12.28 | $-12.56 |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 4th 2025 | Oppenheimer | Initiation | Outperform | $45 |
| November 24th 2025 | Truist | Initiation | Buy | - |
| November 10th 2025 | BTIG Research | Initiation | Buy | $50 |
| November 5th 2025 | Piper Sandler | Initiation | Overweight | $48 |
| March 27th 2025 | JP Morgan | Initiation | Overweight | - |
Earnings History & Surprises
AAPGEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 20, 2025 | — | $-0.24 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.25 | — | — |
Q3 2024 | Aug 22, 2024 | — | $0.31 | — | — |
Q2 2024 | Jun 30, 2024 | — | $0.08 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.25 | — | — |
Q3 2023 | Aug 21, 2023 | — | $-0.81 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.79 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.98 | — | — |
Q3 2022 | Aug 26, 2022 | — | $-0.89 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.97 | — | — |
Q3 2021 | Aug 24, 2021 | — | $-0.94 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.95 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.96 | — | — |
Q3 2020 | Aug 18, 2020 | — | $-0.89 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.89 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-2.03 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-2.04 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.01 | — | — |
Latest News
Reported Earlier, Ascentage Pharma Presents First Phase III POLARIS-1 Dataset At ASH 2025 Showing Best MRD Negativity 66.0% And MRD-Negative CR 64.2% In Newly Diagnosed Ph+ ALL
📈 PositiveReported Earlier, Ascentage Pharma Presents Updated Olverembatinib Data At ASH 2025 Showing 76.7% CCyR And 60% MMR In Second-Line CML-CP
📈 PositiveReported Earlier, Ascentage Pharma Highlights Olverembatinib 4-Year Follow-Up At ASH 2025, Showing EFS Advantage Versus Best Available Therapy In CML-CP
📈 PositiveReported Sunday, Ascentage Pharma Reports Lisaftoclax Plus AZA Shows 31.8% ORR In Venetoclax–Exposed Myeloid Malignancies
📈 PositiveReported Earlier, Ascentage Pharma Says US FDA And EMA Clear Global Registrational Phase III POLARIS-1 Of Olverembatinib Plus Chemotherapy In First-Line Ph+ ALL, With ASH 2025 Data Highlighting ~65% MRD Negativity
📈 PositiveOppenheimer Initiates Coverage On Ascentage Pharma Group with Outperform Rating, Announces Price Target of $45
📈 PositiveReported Earlier, Ascentage Pharma Announced The Publication Of Clinical And Translational Data From A Phase IB Study (Nct03594422) On The Company's Novel Drug, Olverembatinib, In Patients With Gastrointestinal Stromal Tumors, By The Renowned Scientific Journal Signal Transduction And Targeted Therapy
📈 PositiveTruist Securities Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $51
📈 PositiveBTIG Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $50
📈 PositivePiper Sandler Initiates Coverage On Ascentage Pharma Group with Overweight Rating, Announces Price Target of $48
📈 PositiveReported Earlier, Ascentage Pharma To Present Olverembatinib Global Phase III POLARIS-1 Dataset And Lisaftoclax Phase II Oral Study At ASH 2025
📈 PositiveAscentage Pharma Group shares are trading higher after the company announced FDA and EMA clearance for its Phase III GLORA-4 study of Lisaftoclax plus Azacitidine.
📈 PositiveReported Sunday, Ascentage Pharma Announces FDA And EMA Clearance Of Global Registrational Phase III GLORA-4 Study of Lisaftoclax Plus Azacitidine For First-Line Treatment Of Higher-Risk Myelodysplastic Syndrome
📈 PositiveFrequently Asked Questions about AAPG
What is AAPG's current stock price?
What is the analyst price target for AAPG?
What sector is ASCENTAGE PHARMA GROUP INTERNATIONAL in?
What is AAPG's market cap?
Does AAPG pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AAPG for comparison